Pressure BioSciences Inc. (PBIO)
| Market Cap | 8.94M |
| Revenue (ttm) | 1.34M |
| Net Income (ttm) | -16.91M |
| Shares Out | 3.61M |
| EPS (ttm) | -5.90 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $2.30 |
| Previous Close | $2.49 |
| Change ($) | -0.19 |
| Change (%) | -7.63% |
| Day's Open | 2.35 |
| Day's Range | 2.06 - 2.49 |
| Day's Volume | 10,518 |
| 52-Week Range | 1.19 - 4.49 |
News
There are no news available yet.
About PBIO
Pressure BioSciences develops pressure cycling technology (PCT) solutions in North America, Europe, and Asia. Its PCT technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, such as cells and tissues from human, animal, plant, and microbial sources. The company offers Barocycler instrumentations, including Barocycler 2320EXT, Barozyme-HT48, Barocycler HUB440, and The Shredder SG3. It also distributes cell disruption equipment, parts, and consumab... [Read more...]
| Industry Medical Devices | IPO Date Oct 31, 1996 |
| CEO Richard T. Schumacher | Employees 14 |
| Stock Exchange OTCMKTS | Ticker Symbol PBIO |
Financial Performance
In 2019, PBIO's revenue was $1.81 million, a decrease of -26.36% compared to the previous year's $2.46 million. Losses were -$11.66 million, 20.2% more than in 2018.
Analyst Forecasts
The average 12-month stock price forecast for PBIO is 1.57, which is a decrease of -31.74% from the latest price.